Jasper Therapeutics Inc
NASDAQ:JSPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
US |
|
C
|
Chugai Pharmaceutical Co Ltd
DUS:CUP
|
JP |
Intrinsic Value
The intrinsic value of Jasper Therapeutics Inc (JSPR) under the Base Case is 1.23 USD per share.
Compared with the current market price of 0.51 USD, the stock appears
Undervalued by 59% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Jasper Therapeutics Does
Jasper Therapeutics is a biotechnology company developing antibody-based medicines, with its lead program built around briquilimab, an antibody that targets the c-Kit receptor on stem cells and mast cells. The company is trying to use that biology in two main ways: to help prepare patients for stem cell transplant without traditional chemotherapy, and to treat diseases driven by mast cells, such as certain allergic and inflammatory conditions. Its main customers would be hospitals, transplant centers, and specialist doctors if its drugs reach the market.
- Headquarters
- United States of America US
- Employees
- 22
- IPO date
- Nov 20, 2019
Earnings Waterfall
Jasper Therapeutics Inc
The intrinsic value for Jasper Therapeutics Inc (JSPR) under the Base Case is 1.23 USD.
Compared with the current market price of 0.51 USD, the stock appears Undervalued by 59% .